Financial Burden May Be the Largest Barrier to CAR T-Cell Therapy for the Treatment of Multiple Myeloma

Expert breaks down these findings and more from the GLAMM1 study at the 2023 ASH Annual Meeting.

Related Keywords

University Of Kansas ,Kansas ,United States ,California ,San Diego ,American ,Zahra Mahmoudjafari ,Risk Evaluation Mitigation Strategy Center ,American Society Of Hematology ,University Of Kansas Health System In Mission ,Kansas Health System ,Pharmacy Times ,American Society ,Annual Meeting ,Myeloma Medications ,Potential Barriers ,Chimeric Antigen Receptors ,T Cell Engaging Bispecific Antibodies ,